Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | XIAP | P98170 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133303 | 0.91 | ADORA2A (0.60) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6133349 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6133433 | 0.90 | ADORA2A (0.48) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6133816 | 0.90 | HDAC1 (0.52) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6134552 | 0.89 | SMN1; SMN2 (0.49) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6133110 | 0.88 | SMN1; SMN2 (0.49) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6133257 | 0.88 | SMN1; SMN2 (0.56) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6134298 | 0.88 | ADORA2A (0.53) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6133938 | 0.88 | ALK (0.50) | ADORA2AADORA1 | |
| SCHEMBL6133770 | 0.88 | ADORA2A (0.46) | ADORA2AADORA1SMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | ADORA2A 635/4885ADORA1 243/4885SMN1; SMN2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.